Luigi Frigerio

310 - Quality of life after citoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer (eoc)
Malandrino C.,Giulii Capponi M., Busci L., Giordano R., Ansaloni L. and Frigerio L.

Obiective: Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal carcinomatosis (PC) has gradually been accepted as an effective and promising treatment modality for advanced epithelial ovarian cancer (EOC). Limited studies have assessed the effect of CRS+HIPEC in patients’ Quality of Life (QoL) using structured and validated instruments. The purpose of this study was to evaluate the impact of this combined procedure on quality of life in patient’s group with primary or recurrent PC due to EOC.
Materials and methods: A prospective single centre study of 20 patient treated with CRS and HIPEC for EOC (stage IIIC-IV), from December 2010 to November 2014, was conducted using the SF36 questionaire, completed preoperatively and at 3,6 and 12 months after the surgery.
Results: Questionnaire compliance was 100%, 90% 80% and 80% at baseline, 3, 6 and 12 months respectively. Despite initial decline of QoL, the SF36 scores increased during follow up at 6 and 12 months. Physical activity, pain and social activities recovered significantly at 6 months; general health, mental health and vitality showed an improvement during 6 and 12 months; physical and emotional role had slow recovery on the follow-up. In the early postoperative period factors decreasing QoL were the additional operations (25%), the presence of stoma (35%) and the side effects of adjuvant chemotherapy (65%).
Conclusions: Despite complexity of combined procedure, QoL was significantly decreased up to 6 months and returned to basaline at 12 months. This treatment strategy should be considered in selected patients with advanced EOC.